Clinical trials
Clinical Study clinical trials
Below are recruiting clinical study clinical trials, each written for real people, not researchers. We’re tracking 1,741 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07597629RecruitingPhase 2
SYS6023 combination therapy for advanced breast cancer
This trial tests a new drug combination (SYS6023) for advanced breast cancer that has spread or cannot be surgically removed. The treatment targets a protein called HER3, which may help stop cancer growth in patients whose cancer has progressed despite previous treatments.
Harbin, HeilonjiangAges 18 years+ - NCT07601087RecruitingPhase 1
Safety Study of HRS-7156 in Healthy Adults
This is an early-stage safety study of an experimental drug called HRS-7156 in people with no serious health conditions. Researchers will monitor how your body tolerates the drug and how it moves through your system.
Shanghai, Shanghai MunicipalityAges 18–55 - NCT07600749RecruitingPhase 1
MK-4884 study for advanced solid tumors
This early-stage study tests a new drug called MK-4884 in patients with advanced cancers that have spread. The trial includes colorectal, kidney, lung, and bile duct cancers, and aims to find the right dose and see if the drug helps shrink tumors.
St Louis, MissouriAges 18 years+ - NCT07598383RecruitingPhase 2
Gel treatment for mild-to-moderate atopic dermatitis
This study tests a new gel called VC005 to see if it safely reduces itching, redness, and irritation in people with atopic dermatitis (a chronic skin condition). You'll be randomly assigned to either the new gel or a placebo (inactive gel) and apply it to affected areas over several weeks.
Hangzhou, ZhejiangAges 18 years+ - NCT07601178RecruitingPhase 2
Immunotherapy and targeted drugs for advanced triple-negative breast cancer
This trial tests a combination of four drugs—two immunotherapies (QL1706), an anti-angiogenic agent (anlotinib), and chemotherapy (nab-paclitaxel)—as a first-line treatment for advanced triple-negative breast cancer. The goal is to see if this combination slows or stops cancer growth better than standard treatment alone.
Nanjing, JiangsuAges 18–75 - NCT07598578RecruitingEarly Phase 1
New drug combination for hard-to-treat T-cell lymphoma
This study tests a combination of three drugs (azacitidine, chidamide, and a PD-1 inhibitor) for T-cell lymphomas that have returned or stopped responding to previous treatment. The goal is to see if this combination can help shrink the cancer.
SuzhouAges 18–75 - NCT07599371RecruitingPhase 1/Phase 2
Ivoximab and temozolomide for recurring brain tumors
This trial tests a combination of two drugs—ivoximab (a new immunotherapy) and temozolomide (chemotherapy)—to treat gliomas (brain tumors) that have come back or stopped responding to prior treatment. The goal is to see if this combination is safe and effective.
Zhengzhou, HenanAges 18–85 - NCT06717022Recruiting
CHT102 for mesothelin-positive advanced solid tumors
This trial tests a new cell therapy called CHT102 for people with advanced solid tumors that have a certain marker (mesothelin). The treatment is for those who haven't responded to standard therapy or who don't have a standard first-line option.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06564246RecruitingPhase 4
Comparing Vonoprazan vs. Pantoprazole for GERD
This trial tests a newer medication called vonoprazan against the standard treatment pantoprazole for patients with gastroesophageal reflux disease (GERD). The goal is to see which one works better for controlling symptoms like heartburn and acid reflux over 8 weeks.
GizaAges 17–60 - NCT06718738RecruitingPhase 1
IM96 CAR-T for advanced colorectal cancer
This trial tests a new cell therapy called IM96 CAR-T, which targets a protein (GUCY2C) found on tumor cells. It is for people with advanced colorectal or stomach cancer that has not responded to standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT07592585RecruitingPhase 3
Testing VC005 cream for mild-to-moderate eczema in teens and adults
This study tests a new medication called VC005 to treat atopic dermatitis (eczema)—a skin condition causing itching, redness, and inflammation. Researchers want to see if VC005 can safely reduce symptoms in people aged 12 and older with mild-to-moderate cases.
Nanjing, JiangsuAges 12 years+ - NCT07589569RecruitingPhase 2
HRS-7058 for Advanced Pancreatic Cancer Treatment
This study tests a new drug called HRS-7058 in patients with pancreatic cancer that has spread or cannot be removed by surgery. You may qualify if your cancer has already been treated with at least one prior therapy and you have measurable disease on imaging.
Nanjing, JiangsuAges 18–75 - NCT06700395RecruitingPhase 1
Study of TQB2029 for multiple myeloma patients
This trial tests a new injectable drug, TQB2029, for people with multiple myeloma. It aims to see if the drug is safe and effective, and may be an option if you have measurable disease and are in relatively good health.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07593027RecruitingPhase 1/Phase 2
Study of IMC-003 for pulmonary arterial hypertension
This trial tests a new drug called IMC-003 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can help improve symptoms and exercise ability when added to your current PAH medications.
Beijing, Beijing MunicipalityAges 18–75 - NCT07581834RecruitingPhase 2
Dalpiciclib plus hormone therapy for early hormone-positive breast cancer
This study tests whether adding a new drug called dalpiciclib to standard hormone therapy improves outcomes for women with early-stage breast cancer that is hormone-receptor positive. The goal is to see if this combination is more effective and safe than hormone therapy alone.
Fuzhou, FujianAges 18 years+ - NCT07580105Recruiting
AI tool to help diagnose breast cancer from MRI scans
This study tests a new artificial intelligence software called Kenko Breast AI+ that analyzes breast MRI scans to help doctors better detect and monitor breast cancer. If you've had or are planning to have a breast MRI for cancer concerns, this trial might be right for you.
Elche, AlicanteAges 18 years+ - NCT07580586RecruitingPhase 1
Study of BV100's effect on polymyxin B in healthy volunteers
This early-stage study tests how a new drug called BV100 affects how your body processes polymyxin B, an antibiotic. Researchers want to understand how these two drugs interact so they can develop safer treatments.
ViennaAges 18–55 - NCT07579234RecruitingPhase 3
New drug F182112 for hard-to-treat multiple myeloma
This trial tests a new drug called F182112 against standard treatments for multiple myeloma that has stopped responding to previous therapies. The goal is to see if F182112 works better and is safe for patients whose cancer has become resistant to multiple drug classes.
TianjingAges 18 years+ - NCT07584876RecruitingPhase 1
Safety study of a new blood clotting medicine in healthy adults
This is an early-stage safety study testing a new experimental medicine that affects blood clotting in people with no serious health conditions. Researchers want to make sure the medicine is safe and well-tolerated before testing it in patients who need it.
Perth, Western AustraliaAges 18–65 - NCT07578064RecruitingPhase 4
Comparing two treatments for low white blood cells during breast cancer therapy
This study compares two medications—Shengbai Oral Liquid and Leucogen Tablets—to help raise white blood cell counts in breast cancer patients whose counts drop during cancer treatment. Both drugs aim to help your body recover faster and allow you to continue your cancer therapy on schedule.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07571096Recruiting
PCOS and Blood Clotting Risk Assessment Study
This study helps doctors better understand polycystic ovary syndrome (PCOS)—a hormonal condition affecting ovulation—and how it relates to blood clotting problems. Researchers will collect blood samples and health information to create a risk assessment tool.
Guangzhou, GuangdongAges 14–45 - NCT07570563RecruitingPhase 1/Phase 2
T Cell Immunotherapy for Advanced Cancers
This study tests a new immunotherapy using specially engineered immune cells (called TCR-enhanced Vδ2 T cells) to treat blood cancers or solid tumors that haven't responded to standard treatments. The goal is to see if these cells can safely shrink tumors and improve survival.
Beijing, Beijing MunicipalityAges 18–75 - NCT07576439Recruiting
Gum grafting for receding gums
This study tests a gum grafting procedure to cover exposed tooth roots caused by receding gums. It aims to see if the width of the attached gum affects how well the graft works. If you have receding gums and are healthy, you might be a candidate.
Rohtak, HaryanaAges 18–60 - NCT06728852RecruitingPhase 2
Vorolanib for advanced lung cancer after other treatments
This trial tests a targeted therapy pill called Vorolanib for people with advanced non-small cell lung cancer who have already tried at least two other treatments. It aims to see if the drug can help shrink or control the cancer.
Guangzhou, GuangdongAges 18–70
Hear when a new Clinical Study trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for clinical study?
- Yes. Clin2 currently lists 1,741 recruiting clinical study studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a clinical study trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a clinical study trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.